Speedel Pharmaceuticals, Inc. Release: SP100(Tekturna/Rasilex) Demonstrates Potential to Prodtect Kidneys from Damage
6/5/2008 10:28:13 AM
More...
|
Novartis Corporation (NVS) and Speedel Pharmaceuticals, Inc. at Loggerheads Over Tekturna Royalties
11/16/2007 12:40:40 PM
More...
|
Speedel Pharmaceuticals, Inc. Release: New Data Highlights Potential of Spp100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
5/21/2007 10:36:06 AM
More...
|
Speedel Pharmaceuticals, Inc. Release: Shareholders Approve All Proposals at Annual General Meeting
5/10/2007 12:52:18 PM
More...
|
Speedel Pharmaceuticals, Inc. Announces Financial Results for First Quarter 2007
5/4/2007 10:41:08 AM
More...
|
Speedel Pharmaceuticals, Inc. Announces Financial Results For Full Year 2006
3/29/2007 10:30:21 AM
More...
|
Speedel Stops Current SPP301 Phase III Trial In Diabetic Kidney Disease In The Interests Of Patient Safety
12/19/2006 1:35:18 PM
More...
|
Speedel Pharmaceuticals, Inc. Begins Phase IIa Trial With Next Generation Renin Inhibitor
10/31/2006 5:05:31 PM
More...
|
Second Major Milestone For Speedel Pharmaceuticals, Inc. In Its Goal To Develop Renin Inhibitors As Gold Standard Therapy Over The Next Decade
9/28/2006 10:52:09 AM
More...
|
Abbott Laboratories (ABT) Declines Option For Speedel Pharmaceuticals, Inc. Drug
8/17/2006 8:33:02 AM
More...
|
|